IL-31RA Inhibitors & Biosimilars
1 drugsAbout IL-31RA
Interleukin-31 receptor subunit alpha (IL-31RA) is a component of the IL-31 receptor, which also contains OSMRβ. The receptor is expressed on immune cells and sensory neurons, and its activation by IL-31 triggers inflammation and pruritus.
IL-31RA is a therapeutic target for immunological disorders, but there is currently no genetic evidence directly linking it to specific diseases. Targeting IL-31RA holds promise for treating conditions with excessive inflammation and itch.
IL-31RA is targeted by one approved drug, NEMLUVIO, a biologic. GALDERMA LABS LP is the sole company with an approved drug for this target, indicated for immunology.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Chronic Pruritus of Unknown Origin with only 1 trials.
Top Drugs
GALDERMA LABS LP is the only company with an approved drug targeting IL-31RA.
The lack of competition presents an opportunity, but also highlights potential market entry barriers.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets IL-31RA, using biologic (other) modality.
Explore small molecule or alternative modalities to differentiate from existing therapies.
Clinical Trials 37 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 10 | 9 | 0 | 1 | 100% |
| Phase 2 | 11 | 9 | 0 | 2 | 100% |
| Phase 3 | 12 | 9 | 1 | 2 | 90% |
| Phase 4 | 4 | 1 | 1 | 2 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2024 - 2024)
The first and most recent drug approval for IL-31RA was NEMLUVIO in 2024.
The recent approval suggests growing interest, but market saturation is not yet a concern.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: Moderate (9 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 25 clinical trials targeting IL-31RA.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities